The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?

Marie-Louise Vachon; Douglas T. Dieterich

doi:10.1055/s-0031-1297928

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2011; 31(4): 399-409
DOI: 10.1055/s-0031-1297928

The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?

Marie-Louise Vachon¹ , Douglas T. Dieterich²

¹Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec, Canada
²Division of Liver Diseases, Department of Medicine, The Mount Sinai School of Medicine, New York, New York

Abstract

ABSTRACT

The year 2011 marks the dawn of the new era of direct-acting antivirals for hepatitis C. For the first time since 1998, the U.S. Food and Drug Administration approved two new antiviral drugs for the treatment of chronic hepatitis C virus genotype 1. Dual therapy with pegylated interferon and ribavirin is no longer the standard of care for genotype 1. The new treatment paradigm includes one direct-acting antiviral, a protease inhibitor, in combination with pegylated interferon and ribavirin. This combination nearly doubles the chances of response to treatment, but at the cost of increased toxicity. Many agents with different mechanisms of action and improved safety profiles are in clinical development. The holy grail of HCV treatment is an all oral, interferon-free treatment. The ideal regimen will be potent, well tolerated, with minimal drug–drug interactions and once daily. This article covers new concepts of treatment of hepatitis C with DAAs and gives an overview of the recent highlights in direct-acting antiviral development.

KEYWORDS

Hepatitis C - treatment - direct-acting antivirals

Volltext

Referenzen

REFERENCES

1 Kieffer T L, Kwong A D, Picchio G R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother. 2010; 65 (2) 202-212
2 Moradpour D, Penin F, Rice C M. Replication of hepatitis C virus. Nat Rev Microbiol. 2007; 5 (6) 453-463
3 Pawlotsky J M, Chevaliez S, McHutchison J G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007; 132 (5) 1979-1998
4 Ogata N, Alter H J, Miller R H, Purcell R H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991; 88 (8) 3392-3396
5 Bartels D J, Zhou Y, Zhang E Z et al.. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008; 198 (6) 800-807
6 Pawlotsky J M. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis. 2003; 7 (1) 45-66
7 Susser S, Welsch C, Wang Y et al.. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009; 50 (6) 1709-1718
8 Sarrazin C, Kieffer T L, Bartels D et al.. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132 (5) 1767-1777
9 Wagner F, Thompson R, Kantaridis C et al.. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011; 54 (1) 50-59
10 McCown M F, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother. 2009; 53 (5) 2129-2132
11 Lee S S, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther. 2008; 13 (Suppl 1) 9-16
12 Jacobson I M, McHutchison J G, Dusheiko G ADVANCE Study Team et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364 (25) 2405-2416
13 Poordad F, McCone Jr J, Bacon B R SPRINT-2 Investigators et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364 (13) 1195-1206
14 Sulkowski M S, Ceasu E, Asselah T et al.. SILEN-C1: sustained virologic response (SVR) and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV. J Hepatol. 2011; 54 (Suppl 1) S27
15 Zeuzem S, Andreone P, Pol S REALIZE Study Team et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364 (25) 2417-2428
16 Lin T I, Lenz O, Fanning G et al.. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2009; 53 (4) 1377-1385
17 Fried M W, Buti M, Dore G J et al.. Efficacy and safety of TMC435 in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients: 24 week interim results from the PILLAR study. Hepatology. 2010; 52 (Suppl 1) 107A
18 Huisman M T, Snoeys J, Monbaliu J et al.. In vitro studies investigating the mechanisms of interaction between TMC435 and hepatic transporters. Hepatology. 2010; 52 (Suppl 1) 461A
19 Sulkowski M S, Bourliere M, Bronowicki J P et al.. SILEN-C2: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R. J Hepatol. 2011; 24 (Suppl 1) S30
20 Sane R, Podila L, Mathur A et al.. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol. 2011; 54 (Suppl 1) S488
21 Detishin V, Haazen R, Hooijmaijers R et al.. Final results of the pharmacokinetics, efficacy, safety/tolerability of 400 and 600 mg once-daily dosing of ACH-1625 (HCV NS3 protease inhibitor) in HCV genotype 1. J Hepatol. 2011; 54 (Suppl 1) S186-S187
22 Forestier N, Larrey D, Marcellin P et al.. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. J Infect Dis. 2011; 204 (4) 601-608
23 Gane E J, Rouzier R, Stedman C et al.. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol. 2011; 55 (5) 972-979
24 Terrault N, Cooper C, Balart L A et al.. Phase II randomized, partially blind, parallel-group study of oral danoprevir (RG7227) with PegIFN alfa-2a (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study. Hepatology. 2010; 52 (Suppl 1) 73A
25 Rouzier R, Larrey D, Gane E J et al.. Danoprevir plus low-dose ritonavir (DNV/R) in combination with peginterferon alfa-2a (40KD) plus ribavirin (PEGIFN-2a/RBV) in previous null responders. J Hepatol. 2011; 54 (Suppl 1) S28
26 Lok A S, Gardiner D, Lawitz E et al.. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol. 2011; 54 (Suppl 1) S536
27 Mcphee F, Hernandez D, Yu F et al.. Charcterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052. J Hepatol. 2011; 54 (Suppl 1) S28-S29
28 Foster G R, Buggisch P, Marcellin P et al.. Four-week treatment with GS-9256 and tegobuvir (GS-9190) ± RBV ± PEG, results in enhanced viral suppression of follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients. J Hepatol. 2011; 54 (Suppl 1) S172
29 Wong K A, Bae A, Ku K et al.. Genotypic and phenotypic characterization of HCV resistance from a multiple dose clinical trial of GS-9451, a novel NS3 protease inhibitor. J Hepatol. 2011; 54 (Suppl 1) S493
30 Tong L, Mwangi J, Roy A et al.. In vitro studies on the potential for the hepatitis C virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination. J Hepatol. 2011; 54 (Suppl 1) S487
31 Lawitz E, Rodriguez-Torres M, Denning J et al.. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA <LOD at day 14: first purine/pyrimidine clinical combination cata (The NUCLEAR Study). J Hepatol. 2011; 54 (Suppl 1) S543
32 Lalezari J, Lawitz E, Rodriguez-Torres M et al.. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naïve patients with GT2/GT3. J Hepatol. 2011; 54 (Suppl 1) S28
33 McCown M F, Rajyaguru S, Le Pogam S et al.. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother. 2008; 52 (5) 1604-1612
34 Lawitz E, Rodriquez-Torres M, Rustgi V K et al.. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2A plus ribavirin in treatment-naïve genotype 1 chronic HCV patients. J Hepatol. 2010; 52 (Suppl 1) S467
35 Gao M, Nettles R E, Belema M et al.. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010; 465 (7294) 96-100
36 Tellinghuisen T L, Foss K L, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 2008; 4 (3) e1000032
37 Qiu D, Lemm J A, O’Boyle II D R et al.. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol. 2011; 92 (Pt 11) 2502-2511
38 Nettles R E, Gao M, Bifano M et al.. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011; Epub ahead of print
39 Fridell R A, Wang C, Sun J H et al.. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations. Hepatology. 2011; Epub ahead of print
40 Fridell R A, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010; 54 (9) 3641-3650
41 Crabbé R, Vuagniaux G, Dumont J M, Nicolas-Métral V, Marfurt J, Novaroli L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs. 2009; 18 (2) 211-220
42 Flisiak R, Feinman S V, Jablkowski M et al.. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology. 2009; 49 (5) 1460-1468
43 Flisiak R, Pawlotsky J, Crabbé R et al.. Once daily alisporivir (Deb025) plus PEGIFNalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naïve patients. J Hepatol. 2011; 54 (Suppl 1) S2
44 Coelmont L, Hanoulle X, Chatterji U et al.. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE. 2010; 5 (10) e13687

Marie-Louise VachonM.D. M.Sc.

Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, CHUL

Rm. S-796, 2705 Blvd. Laurier, Quebec City, Quebec, Canada G1V 4G2

eMail: Marie-Louise.Vachon@mail.chuq.qc.ca